Effective dose 50 method as the minimal clinically important difference: Evidence from depression trials

Area of Science:

• Psychiatry and Mental Health
• Clinical Psychology
• Health Outcomes Research

Background:

• Existing minimal clinically important difference (MCID) research for depression and anxiety often relies on population averages.
• This limitation overlooks the variability in patient experiences and treatment responses based on initial symptom severity.

Purpose of the Study:

• To determine the MCID for depression and anxiety across a spectrum of baseline severity.
• To develop a more precise and individualized approach to measuring clinically meaningful change in mental health.

Main Methods:

• Utilized secondary data from two randomized controlled trials for depression (n=1,122).
• Calibrated the Global Rating of Change with the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) scales.
• Defined MCID using the Effective Dose 50 (ED50) method, representing a 50% probability of patients feeling better relative to their baseline severity.

Main Results:

• MCID estimates varied significantly with baseline severity.
• For the PHQ-9, MCID ranged from no change in very mild cases to 14 points (52%) in very severe cases.
• For the GAD-7, MCID ranged from no change in very mild cases to 10 points (48%) in very severe cases.
• Average MCID estimates were 3.7 points (23%) for PHQ-9 and 3.3 points (28%) for GAD-7.

Conclusions:

• The Effective Dose 50 (ED50) method provides more precise MCID estimates across the full range of baseline severity.
• This approach offers greater precision than population average estimates, albeit with increased complexity.
• These findings are crucial for tailoring treatment evaluations and clinical practice by adjusting MCID based on specific patient populations and their baseline severity.